SCHEMBL1365077

SCHEMBL1365077

COc1ccccc1-c1ncc(C(=O)NC2CCN(CC(F)(F)F)CC2)cn1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 12/20 0.62
KDM1A O60341 1/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
DCLK1 O15075 1/20 0.48
BRD4 O60885 1/20 0.48
LRRK2 Q5S007 1/20 0.48
ALDH1A1 P00352 1/20 0.46
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
HTR7 P34969 1/20 0.46
SSTR5 P35346 1/20 0.46
SLC6A12 P48065 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367141 0.90 HPGDS (0.62) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1366544 0.88 HPGDS (0.60) HPGDSKDM1ABCHEACHEALDH1A1
SCHEMBL1367480 0.88 HPGDS (0.64) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1368956 0.87 HPGDS (0.63) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1367299 0.87 HPGDS (0.65) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1367026 0.87 HPGDS (0.65) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1364571 0.86 HPGDS (0.62) HPGDSKDM1ABCHEACHEPRKAB2
SCHEMBL1364959 0.86 HPGDS (0.64) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1367215 0.86 HPGDS (0.64) HPGDSKDM1APRKAB2PRKAG1PRKAA2
SCHEMBL1364797 0.85 HPGDS (0.63) HPGDSKDM1APRKAB2PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S HPGDS 99/4885KDM1A 2416/4885BCHE 624/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S HPGDS 99/4885KDM1A 2416/4885BCHE 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.